Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: Investigational (Tier 3)GRADE: Moderate

Investigational / Research Priority

Ophthalmic applications of hirudotherapy are not included in FDA 510(k) clearance for medicinal leeches. No ophthalmic indication has received specific regulatory clearance in the United States, the European Union, or any other major jurisdiction.

Investigational Application

Ophthalmology is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Ophthalmic hirudotherapy occupies a distinctive position within investigational leech medicine. The eye is an organ of exquisite vascular sensitivity: a rise of a few millimeters of mercury in intraocular pressure, a microvascular occlusion in a retinal arteriole, or a thrombus in the central retinal vein can destroy vision within hours. Published international clinical experience documents the largest cumulative dataset among investigational specialties — over 1,100 patients across glaucoma, retinal vascular disease, inflammatory eye conditions, and visual rehabilitation. The Moscow MNTC “Eye Microsurgery” treated more than 300 patients annually over 15+ years. No randomized controlled trial has been performed for any ophthalmic indication.

Fundamento biológico

Glaucoma Mechanisms

Hirudin-mediated anticoagulation may reduce ciliary body secretion; hyaluronidase-facilitated tissue permeability may improve trabecular outflow; histamine-like vasodilation may enhance uveal blood flow. Controlled blood extraction reduces orbital venous pressure.

Retinal Vascular Pathways

Hirudin inhibits thrombin; destabilase-M lyses cross-linked fibrin; calin and saratin suppress platelet adhesion; lipase/cholesterol esterase fractions exert anti-atherosclerotic effects. Published research describes enhanced retinal perfusion and collateral development.

Anti-Inflammatory Cascade

Eglins block neutrophil elastase and cathepsin G; C1s complement inhibitor modulates classical pathway; hyaluronidase enhances lymphatic drainage; LDTI tryptase inhibitor attenuates mast cell-mediated inflammation in autoimmune ocular conditions.

The convergence of anticoagulant, fibrinolytic, anti-inflammatory, and vasoactive agents in a single biological secretion is particularly relevant to ophthalmology, where pathophysiologic mechanisms across glaucoma, retinal vascular disease, and inflammatory conditions overlap.

Evidencia clínica

GRADE Evidence Level: Low

Observational studies or RCTs with serious limitations

Published Clinical Evidence — All Ophthalmic Indications
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Mozherenkov et al. 1998	Comparative cohort	Acute angle-closure glaucoma (n=302)	HT (2-3 leeches, temple) + standard tx vs standard tx alone	Attack resolution rate	87% with HT (n=177) vs 77% without (n=125); p < 0.05 Level III; strongest comparative data for any ophthalmic indication
Bondareva & Zhitenev 1998	Case series	Acute glaucoma — emergency protocol (n=500)	Leeches + acetazolamide + pilocarpine	Pain, congestion, corneal edema	Pain reduction/resolution at 30-40 min post-application Level IV; largest single ophthalmic HT cohort
Bagdasarova 1973	Prospective cohort — tonometric	Chronic glaucoma (n=181)	Leech to temporal region; IOP at 1, 3, 24 h	Intraocular pressure	Significant IOP reduction within 1 h; max at 1-3 h; return toward baseline at 24 h Level IV; consistent temporal pattern
Bagdasarova 1973	Prospective cohort — tonographic	Chronic glaucoma — aqueous dynamics (n=159)	Leech application; tonographic measurement	True IOP, outflow facility, aqueous secretion	All three significantly improved; outflow facility markedly increased Level IV; mechanism data — genuine outflow improvement, not transient volume change
Semikova & Bondareva 1995	Prospective case series	Keratitis, iridocyclitis, uveitis — MNTC program (n=300)	Periorbital application; 6-10 sessions q2-3 days	Infiltrate, tenderness, synechiae, mydriatic response	Corneal clearing; synechiae lysis; enhanced mydriatic effect Level IV; >300 pts/year for >15 years
Semikova et al. 1999	Case series	Post-intraocular surgery complications (n=300)	Single HT session postoperatively	Complication resolution	Single session sufficient in many cases; reduced revision needs Level IV; annual MNTC volume
Bondareva 1998	Case series	Chronic retinal/optic nerve vascular disease (n=12)	10 sessions; alternating temporal/mastoid; 2-4 leeches	Visual acuity, visual field	VA: 0.01→0.1, 0.1→0.5-0.6, 0.08→0.3, 0.8→1.0; VF +10-20° Level IV; chronic disease typically refractory to standard treatment
Mukhanko & Kulanin 2001	Comparative cohort	Blind/visually impaired — rehabilitation (n=540)	HT + mineral water therapy vs no HT	Visual function improvement	69% improvement with HT vs 50% controls; no deterioration Level III; combined intervention limits attribution
Vedeneeva & Medvedeva 2000	Case report	Thyroid ophthalmopathy (n=1)	HT for orbital edema, proptosis, diplopia	Clinical response	Successful treatment Level V
Yoyleva et al. 1999	Case series	Optic neuropathies (n=NR)	HT + magnetostimulation	Visual function	Enhanced efficacy with combination therapy Level IV; n not reported

Glaucoma: Strongest Comparative Data

Mozherenkov et al. (1998) provided the closest approximation to comparative data: in 302 patients with acute angle-closure glaucoma, the hirudotherapy group achieved 87% attack resolution versus 77% with standard treatment alone (p<0.05). Bondareva and Zhitenev (1998) documented 500 patients receiving leeches alongside acetazolamide and pilocarpine, with pain reduction at 30-40 minutes post-application.

Bagdasarova (1973) conducted tonographic analysis in 340 patients. True IOP decreased, outflow facility increased markedly, and aqueous humor secretion showed compensatory increase — a homeostatic response to improved outflow, not a pathologic rise. These data provide a physiologic explanation for clinical IOP reductions and suggest genuine improvement in outflow physiology rather than transient blood volume reduction.

Physiologic Mechanism Evidence

The Bagdasarova tonographic data are noteworthy: they demonstrate a specific mechanism (improved outflow facility) rather than documenting only clinical endpoints. The compensatory secretion increase is consistent with restored outflow capacity.

Retinal Vascular Disease: Visual Acuity Outcomes

Bondareva (1998) treated 12 patients with chronic retinal vascular disease (10 sessions, alternating temporal/mastoid). Visual acuity gains were clinically significant: 0.01 to 0.1 (n=2), 0.1 to 0.5-0.6 (n=5), 0.08 to 0.3 (n=3), 0.8 to 1.0 (n=1), with visual field expansion of 10-20 degrees. These represent functional transitions from near-blindness to ambulatory vision in disease stages generally refractory to standard treatment.

Inflammatory Eye Disease: MNTC Program

Keratitis & Iridocyclitis

Published research documents decreased corneal infiltrate and progressive clearing. Enhanced mydriatic drug action was reported — suggesting SGS-mediated improvement in microcirculatory drug penetration. Posterior synechiae breakdown with pupil dilation documented in iridocyclitis cases.

Uveitis & Postoperative

Combined therapy produced reduced vitreous precipitates and prevention of coarse vitreous strands. Post-intraocular surgery complications (iritis, macular edema, elevated IOP) managed with single session in many cases, reducing need for additional intervention.

Additional Indications

Radiation Complications

Semikova (1998) described leech application for radiation-induced inflammation following uveal melanoma treatment. Ocular hemorrhage (hemophthalmos) documented as responsive to SGS fibrinolytic activity.

Optic Neuropathy

Retrobulbar neuritis and papilledema responded in acute stage. Yoyleva et al. (1999) reported enhanced efficacy when combined with magnetostimulation. Sympathetic ophthalmia particularly emphasized.

Rehabilitation

Among 540 patients: 69% improvement with HT vs 50% controls; improvement (n=448) or stabilization (n=92) with no deterioration (Mukhanko & Kulanin 2001).

Protocolo clínico — Aplicación periorbitaria

Standard Protocol

Preparation: Clean temple/mastoid; no residual antiseptic
Method: 2 leeches in glass vial pressed against temple or mastoid
Duration: Until engorgement and spontaneous detachment (20-40 min)
Course: 6-10 sessions at 2-3 day intervals
Bilateral: 2 leeches (unilateral) or 4 leeches (bilateral)

Acute Glaucoma Crisis

Leeches: 2-3 to temple; +1 mastoid in severe cases
Assessment: Re-evaluate at 30-40 min for pain/IOP response
Sessions: Single session may suffice
Integration: Adjunct to acetazolamide + pilocarpine only

Site Selection by Indication
Indication	Primary Site	Alternative	Leeches	Course
Inflammatory disease	Temple (ipsilateral)	Mastoid	2	6-10 sessions, q2-3d
Chronic glaucoma	Temple (ipsilateral)	Mastoid	2	6-10 sessions, q2-3d
Acute glaucoma	Temple (ipsilateral)	Mastoid (severe)	2-3 (+1)	Single; reassess 30-40 min
Retinal vascular	Temple (alternating)	Mastoid (alternating)	2 or 4	10 sessions
Postoperative	Temple (ipsilateral)	Mastoid	2	Single session often sufficient

Pre-Procedure Assessment

Complete ophthalmic exam: VA, IOP (Goldmann tonometry), slit-lamp, dilated fundus
Visual field testing (automated perimetry) for glaucoma/retinal vascular patients
CBC, coagulation panel, medication review (anticoagulants, antiplatelets)
Prior leech exposure and allergy history assessment
Counseling: periorbital ecchymosis, bleeding duration, cosmetic scarring

Post-Procedure Monitoring

Sterile dressing; expect 4 to 24 hours post-detachment oozing
IOP at 1, 3, and 24 hours (glaucoma patients per Bagdasarova protocol)
VA and visual field testing at course completion
Periorbital infection assessment at each session

Consideraciones de seguridad

Critical Safety Requirements

Globe proximity: Leeches must never be applied to eyelids or conjunctiva. The glass vial containment method is mandatory — prevents migration toward the eye throughout the entire application period.
Cavernous sinus pathway: The periorbital region drains into the cavernous sinus via valveless ophthalmic veins. Aeromonas hydrophilacould theoretically propagate intracranially. No such case reported; prophylactic antibiotics (fluoroquinolone or TMP-SMX) should be considered in immunocompromised patients.
Anticoagulant interactions: Patients on warfarin, DOACs, heparin, aspirin, or clopidogrel may experience prolonged bleeding. Coagulation status must be assessed before treatment initiation.

Periorbital Ecchymosis

Post-detachment bleeding may produce “black eye.” Self-limiting, resolving within 7-10 days. Pre-treatment counseling required.

Infection Risk

Prophylactic antibiotics recommended for immunocompromised patients. Standard wound care. Heightened surveillance for cavernous sinus drainage pathway.

Cosmetic Scarring

Triradiate bite mark heals as small, pale scar. Usually inconspicuous on temple skin. Patients require informed consent regarding facial scarring.

Medication Interactions in Ophthalmic Hirudotherapy
Medication	Interaction	Action
Warfarin, DOACs, heparin	Additive anticoagulant effect; prolonged bleeding	Assess coagulation; coordinate with prescriber
Aspirin, clopidogrel	Additive antiplatelet via calin/saratin	Bleeding time assessment; ecchymosis counseling
Mydriatics (atropine, tropicamide)	Enhanced effect reported (improved drug penetration)	Monitor for excessive mydriasis
Acetazolamide (oral)	Additive IOP reduction via different mechanisms	Documented in acute glaucoma protocols
Prostaglandin analogs	No published data	Theoretical additive benefit; no safety data

Brechas de evidencia y prioridades de investigación

Methodological Limitations

No RCTs for any ophthalmic indication
All evidence Level III-IV (comparative cohorts, case series)
Multiple combined-intervention studies limit attribution
Periorbital application inherently difficult to blind
Geographically homogeneous populations (Russian centers)
Non-standardized outcome measures across studies

Priority Research Areas

Pragmatic RCT: adjunctive HT in acute angle-closure glaucoma
Prospective registry with ETDRS VA, Goldmann IOP, automated VF
Dose-response: optimal leech count, frequency, course duration
SGS pharmacokinetics in periorbital tissues
Long-term follow-up: IOP durability, VA stability at 6-12 months
Infection surveillance: cavernous sinus pathway risk

ASH supports development of prospective registries with standardized endpoints. The consistent direction of benefit across multiple investigators and institutions over 15+ years provides a foundation for rigorous prospective studies. Acute angle-closure glaucoma (n=302, p<0.05) is the most promising candidate for a pragmatic RCT.

Conclusiones clave

Largest investigational evidence base: Over 1,100 patients across glaucoma, retinal vascular, and inflammatory eye disease, with >300 patients/year treated at specialized centers for over 15 years.

Strongest comparative data: 87% vs 77% attack resolution in acute angle-closure glaucoma (p<0.05; Mozherenkov 1998, n=302) — adjunct to standard pharmacologic management.

Documented physiologic mechanism: Tonographic studies (n=340) demonstrate improved aqueous humor outflow facility — genuine physiologic improvement, not transient blood volume reduction.

Multi-target SGS pharmacology: Hirudin (anticoagulation), destabilase (fibrinolysis), hyaluronidase (permeability), eglins (anti-inflammatory), C1s inhibitor (complement), lipase (vascular protection).

Mandatory safety protocol: Glass vial containment prevents globe migration. Cavernous sinus drainage pathway requires heightened infection surveillance. Anticoagulant screening essential.

No RCTs to date: All evidence Level III-IV. Consistent benefit direction across investigators and institutions supports investigation but does not constitute definitive clinical proof.

Referencias

Bagdasarova, N. A. (1973). Hirudotherapy in glaucoma: Tonometric and tonographic studies (n=340).
Bakalova, T. P., Arkhipova, L. T., et al. (2001). Combined therapy for vascular eye disease.
Bondareva, G. S. (1998). Hirudotherapy in chronic retinal vascular disease (n=12).
Bondareva, G. S., & Zhiteneva, E. A. (1998). Ophthalmic emergencies and hirudotherapy.
Chaban, T. N., & Savinov, V. A. (1995). Outpatient hirudotherapy for corneal disease and glaucoma.
Dorogova, V. B. (1935). Leeches in diseases of the visual organ.
Ivanova, L. M. (1998). Combined hirudotherapy and acupuncture for retinal vascular disease.
Kartasheva, E. A. (1979). Leeches in acute angle-closure glaucoma: A critical assessment.
Mozherenkov, V. P., et al. (1998). Comparative outcomes in acute glaucoma (n=302).
Mukhanko, L. E., & Kulanin, V. I. (2001). Rehabilitation of visually impaired (n=540).
Mukhanko, L. E., & Kulanin, V. I. (2003). Extended follow-up of visual rehabilitation.
Semikova, T. S. (1998). Leech application in choroidal melanoma radiation complications.
Semikova, T. S., & Bondareva, G. S. (1995). Inflammatory eye disease: MNTC program.
Semikova, T. S., et al. (1999). Postoperative management with hirudotherapy at MNTC.
Vedeneeva, Z. V., & Medvedeva, N. G. (2000). Hirudotherapy for thyroid ophthalmopathy.
Yoyleva, S. A., et al. (1999). Combined HT and magnetostimulation for optic neuropathies.

Oftalmología